



Array Patch

AWARD WINNING MICRONEEDLE
PATCH DELIVERY TECHNOLOGY


COMPANY PRESENTATION




Array Patch | **DERMAP™ – REIMAGINED THE NEEDLE**



ArrayPatch | DERMAP™ – REIMAGINED THE NEEDLE



PIPELINE OPPORTUNITIES



GLP-DERMAP™


Diabetics/Weight Control

RATIONALE

- Pain-free and non-invasive alternative to traditional subcutaneous injections
- Increase compliance, especially in pediatric, elderly, or needle-phobics.
- can be engineered for sustained or controlled release.

MARKET

\$139BN



VIS-DERMAP™

Basal Cell Carcinoma

- Certain areas of body not suitable for surgery – e.g. Face, elbow, knee
- Oral medication shows negligible systemic exposure
- VIS-DerMap™ offers potential solution applying patch adjacent to BCC

\$10BN




ITZ-DERMAP™

Nail Fungal Infection

- 1 in 4 people can be infected with nail fungal
- Current treatment take up to 1 year
- Only 1 out 3 show cure response
- Current treatment carry severe liver toxicity.

\$6BN

PIPELINE OPPORTUNITIES



GLP-DERMAP™

Diabetics/Weight Control

RATIONALE

- Pain-free and non-invasive alternative to traditional subcutaneous injections
- Increase compliance, especially in pediatric, elderly, or needle-phobics.
- can be engineered for sustained or controlled release.

MARKET

\$139BN

GLP-1 - A GROWING MARKET BUT UNMET NEED REMAINS

\$139B¹
(By 2030)

GLP-1 THERAPEUTICS
MARKET

\$36B²
(2025)

MONJARO/ZEPBOUND
ANNUAL GLOBAL REVENUE

80%³

INJECTABLES DOMINATE



Injectable GLP-1 limitations: adherence impacted by needle aversion, injection-site reactions, cold-chain requirements



Discontinuation rates as high as 40% with current delivery methods



Millions of eligible obesity and diabetes patients remain untreated

Simpler and more patient-friendly delivery formats could address needs and substantially expand the market

TRADITIONAL INJECTION



PATCH TECHNOLOGY



**THE SOLUTION: A DISSOLVING GLP-1
MICRONEEDLE PATCH**

MICRONEEDLE PATCH DELIVERY CAN ADDRESS UNMET NEED


ISSUES LIMITING UPTAKE/DRIVING DISCONTINUATIONS OF INJECTABLES



Administration pain



Needle fear



Delivery site reactions



Cold storage requirements



Needle disposal requirements


ADDRESSED BY MICRONEEDLE PATCH DELIVERY



MICRONEEDLE PATCH DELIVERY BENEFITS

- Better convenience
- Improve adherence
- Expand access
- Grow market
- Safe


UNIQUE MICRONEEDLE PATCH DELIVERY TECHNOLOGY – 100% PEPTIDE / NO POLYMER



- Peptides converted to glassy state, filled into pre-fabricated molds
- Made entirely of peptide; no polymer

Typical patch profile:


Description	Optimal	Limit
Patch size	0.5-1cm ²	2-2.5cm ²
Injectable dose/patch	3-5mg	10-12mg
Length	500µm	800µm



	Semaglutide		GLP-DerMap TPP**
Branded Product	Wegovy® Ozempic®	Rybelsus®	GLP-DerMap
Admin	Injection	Oral	Patch
Dosage	0.25 – 2.4mg (once weekly)	3-14mg (once daily)	3-5mg (once weekly)
Storage	(2-8°C)	Room temp.	Room temp.
Status	Launched	Launched	Pre-clinical

*WO2025032025A1 **Target product profile based on preliminary data


SKIN PENETRATION



- Demonstrated the successful penetration of the stratum corneum and rapid, complete dissolution post-application

Neonatal porcine skin was used to assess the ability of model peptide to penetrate the stratum corneum.


Manufacturing



- GLP-1s
- Hormone peptides for IVF
- GLP2 agonist
- Peptides for multiple sclerosis
- Cosmetic peptides

Prototype microneedle patches were fabricated from different peptides


PHARMACOKINETICS



- Similar PK profile of patch and SC injection
- Pharmacokinetic data consistent with therapeutic exposure for GLP-1 class
- Large scale animal study planned

Compare peptide microneedle patch v IP injection in rats (N=3); 50+ a.a. peptide [Liu et al. 2025].

STABILITY




- Early stability data supports formulation viability under ambient storage conditions

HPLC and LCMS test on glass microneedle after 6 months storage at room temperature

AN EFFICIENT PATH TO US MARKET VIA 505(B)(2)


GLP-1 agonist regulated as drug not biologic by US FDA – GLP1-DerMap can leverage the US FDA **505(b)(2) regulatory pathway** — reducing clinical risk, development timelines, and capital requirements relative to a full NDA.



✓ **Key Advantage:** Approved peptide safety and efficacy data are already on file — only new delivery-specific data is required, significantly reducing regulatory risk and clinical burden.


i **Risk Reduction:** PK/PD bridging design focuses on demonstrating similar PK/PD to the reference listed drug, not re-proving the therapeutic effect of GLP-1 agonists.

Array Patch | GLP-DERMAP – PATH TO US APPROVAL VIA 505(B)(2) PATHWAY*



- In US semaglutide regulated as drug: expedited FDA 505(b)(2) regulatory path available
- In EU approval will require Phase 1/2/3 clinical trials as no hybrid path available


ALL COMPETITOR DISSOLVING
MICRONEEDLE PATCH
TECHNOLOGY



- Up to 90% of microneedle made from polymer to ensure structural integrity
- As little as 10% room left for peptide

- ✗ Reduces drug loading potential
- ✗ Reduces efficacy and dosing flexibility
- ✗ Potentially increases safety risk
- ✗ Stability and aggregation with Peptides/Proteins

DERMAP™ DISSOLVING
MICRONEEDLE PATCH
TECHNOLOGY



- Uniquely, microneedles made from 100% peptide, no polymer
- Basis of ArrayPatch patent¹

- ✓ Maximum drug loading potential
- ✓ Increases efficacy and dosing flexibility
- ✓ Potentially reduces safety risk
- ✓ Broad therapeutic application

¹Patent: [WO2020250210A1](#)

ArrayPatch

DERMAP – DIFFERENTIATED VERSUS COMPETING PLATFORMS

Only polymer-free, 100% peptide loaded dissolving microneedles

COMPANY	PLATFORM	GLP-1	STATUS	COMMENT
	Clopam ® dissolving microneedle patch; included polymer	Semaglutide	Phase 1 (80% bioavailability; 160x > oral semaglutide)	Supports clinical potential of a GLP-1 patch
	MIMIX ™ microneedle patch – dissolving tips; including polymer	Semaglutide	Pre-clinical (bioavailability comparable with injection; 2 nmol/kg dose)	Complex delivery device; less dosing flexibility; peptide-polymer compatibility
	GelMA - drug-loaded reservoir tip on hydrogel microneedle array	Semaglutide	Pre-clinical	Complex delivery device; less dosing flexibility; peptide-polymer compatibility
	DerMap ™ – 100% peptide, maximum loading capacity	Semaglutide & Others	Pre-clinical	Simple delivery device; dosing flexibility up to 8mg; No polymer: robust stability

PARTNER WITH ARRAYPATCH TO TRANSFORM GLP-1 DELIVERY

Next-generation peptide delivery via world's first polymer-free dissolving microneedle platform

Differentiated Technology	Partnering Opportunity
 World's first dissolving microneedle comprising 100% peptide	Seeking a strategic co-development & licensing partner
 No polymer, maximising payload potential	ArrayPatch leads formulation, CMC and preclinical development
 Needle-free delivery designed to improve patient adherence	Partner leads clinical development, registration & commercialisation
 Platform technology applicable across multiple peptide therapeutics	Global or regional licensing opportunities available

MULTIPLE STRATEGIC EXIT OPPORTUNITIES



WHY STRATEGIC BUYERS WILL BE INTERESTED



Access to a differentiated microneedle delivery platform



Lifecycle management for blockbuster drugs (e.g. GLP-1s)



Large addressable markets across multiple indications



Needle-free, patient-friendly delivery across peptides and small molecules



CDMOs gain proprietary capability to expand into high-growth platforms



POTENTIAL STRATEGIC ACQUIRERS

PHARMA



CDMOS & DRUG DELIVERY COMPANIES



COMPARABLE EXIT BENCHMARKS¹



Early Platform Licensing Deals

\$50M – \$300M+



Clinical-Stage Platform Acquisitions

\$300M – \$1B+



Obesity / Metabolic Strategic Acquisitions

\$1B – \$10B+
(and growing)



STRONG STRATEGIC RATIONALE. BROAD APPLICATIONS. SIGNIFICANT VALUE POTENTIAL.

Well positioned for a high-value exit through acquisition, partnership or licensing.

¹ Source: Company filings, press releases, and industry reports.



CEO/Founder
Waleed Faisal

- Led several EI projects
- Raise > €3m funding
- Lead inventor DerMap
- Quality Assurance at Xeolas Pharmaceuticals



CFO
Darren Cunningham

- >25 yrs industry experience
- Fundraising > \$100M
- Ex Elan & Amarin (NASDAQ)
- Co-founder/ former CEO Inflection & Mysthera



CDO
Erik Doevendans

- >25 years regulatory affairs and drug development
- Manufacturing operations/ product development
- QC/QA specialist



COO
Ryan Bamsey

- >25 years develop & launch microneedle products
- Design and implement QMS
- >4 years product development



Array Patch

Founder/CEO – Dr. Waleed Faisal
E-Mail: waleed.faisal@array-patch.com
Mobile: +353 85 7223337
Web: www.array-patch.com

